Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX vs Dysport in Cervical Dystonia
NCT00432341Phase 4Terminated
- Sponsor
- Allergan
- Start
- Jun 2007
- Primary completion
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised trial of onabotulinumtoxinA in cervical dystonia (CD) (2 arms), sponsored by Allergan. Primary endpoint: Duration of Treatment Benefit at 20 weeks. Started Jun 2007; status: terminated.
02
Drugs
onabotulinumtoxinA
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT00432341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432341.